Analysts at Canaccord Genuity Group Initiate Coverage on Marker Therapeutics (NASDAQ:MRKR)

On March 8, 2025, Canaccord Genuity Group announced it has started coverage of Marker Therapeutics (NASDAQ:MRKR) in a research report aimed at investors. The firm assigned a ‘buy’ rating to the company and set a price target of $8.00 per share.

In a separate development, Brookline Capital Management also upgraded Marker Therapeutics to a ‘strong-buy’ rating in a report dated February 10, 2025.

Marker Therapeutics Experiences Trading Decline

As of Wednesday, Marker Therapeutics shares were trading at $1.50, reflecting a decline of 6.8%. Over the past year, the company's stock has seen a low of $1.35 and a high of $5.99. The stock's 50-day simple moving average is $2.16, while its 200-day simple moving average is $2.97.

Recent Insider Transactions

Recently, there have been notable transactions involving insiders of Marker Therapeutics. On December 23, 2024, Director Steve Elms purchased 11,085 shares at an average price of $3.20 per share, totaling around $35,472. Following this purchase, Elms now holds 325,370 shares of the company, valued at about $1,041,184, marking a 3.53% increase in his position.

In another transaction on the same date, Enterprise Associates 16 New acquired 554,250 shares at an average price of $3.20 per share, with a total cost of approximately $1,773,600. This acquisition increased their stake by 51.73%, bringing their total to 1,625,678 shares valued at around $5,202,169.60. Insiders currently own about 14.50% of the company’s stock.

Institutional Investors and Trading Activity

A number of institutional investors have recently adjusted their holdings in Marker Therapeutics. Millennium Management LLC made a new investment during the fourth quarter worth $50,000, while Invst LLC invested $56,000 in the third quarter. Northern Trust Corp increased its stake by 66.9% in the fourth quarter, holding 54,156 shares valued at $168,000 after adding 21,703 shares.

LPL Financial LLC also established a new position valued at $248,000 in the fourth quarter. Additionally, Aisling Capital Management LP raised its stake by 3.5%, owning 325,370 shares worth approximately $1,012,000 after acquiring 11,084 additional shares. Overall, institutional investors control about 22.39% of Marker Therapeutics' stock.

About Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing innovative T cell-based immunotherapies for various malignancies, including hematological cancers and solid tumor indications. The company's technology enables the creation of non-engineered tumor-specific T cells that can recognize a variety of tumor-associated antigens.

stock, analysis, investment